PMRA.F Pharma Mar SAU

Healthcare Biotechnology Frankfurt Exchange
67.90 EUR
Close of Nov 13, 2026
64.05 104.30
Market cap
EUR 1.17B
P/E
17.3x
P/B
5.04x
ROE
4.9%
Dividend yield
1.19%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PMRA.F undervalued?

Graham number
Price67.90
Graham value34.52
Premium96.7%

PMRA.F trades 96.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharma Mar SAU fundamental analysis

No fundamental analysis for Pharma Mar SAU yet.

Pharma Mar SAU stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharma Mar SAU

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue…

Full company profile